- Home
- REBN vs MYNZ Comparison
REBN vs MYNZ Comparison
Compare REBN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | MYNZ |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 8.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REBN | MYNZ |
|---|---|---|
| Price | $1.50 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 61.9K | ★ 197.9K |
| Earning Date | 11-19-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,663,303.00 | $659,935.00 |
| Revenue This Year | $335.98 | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.09 | N/A |
| 52 Week Low | $1.14 | $0.92 |
| 52 Week High | $8.30 | $8.20 |
Technical Indicators
Market Signals| Indicator | REBN | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 53.56 |
| Support Level | $1.62 | $1.00 |
| Resistance Level | $1.80 | $1.15 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.54 | 87.76 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.